The JAK inhibitor cream for hand eczema will serve a large market in Europe and help the Danish dermatology specialist expand its strong position in dermatology. 

Roche is taking a more hard-nosed approach to portfolio prioritization, and said in its Q2 call that it believes it can move faster with a more slimmed down R&D pipeline.

Big biopharma is struggling to find the next generation of cancer immunotherapies, but the sector’s smallest companies might just have the platforms of the future.

Adding Oxford to its roster will help Apollo widen its net for potential first-in-class therapies, and connects with the university’s ambition to build world-beating spin-outs.

Flush with cash, the controlling stakeholder of Novo Nordisk’s life sciences investment arm is increasing its financing of other biopharma innovators.

New modalities and potential best-in-class challengers have excited investors in 2024 to date, but companies whose drugs have underperformed on the market have been punished.